Emma Ungstrup’s Post

View profile for Emma Ungstrup, graphic

CAR-T therapies | European Regulatory Affairs l Global Drug Development

Was a fascinating Ad Com yesterday @FDA for the first-ever therapy to use CRISPR/Cas9 gene editing (Vertex's very impressive exa-cel gene therapy for sickle cell disease)- "Off target" gene editing, genomic heterogeneity, genome sequencing of edits, and the long term biological consequences of undesired edits was up for discussion. Take homes are its really important to analyse the genetic changes after editing and to hold samples back for long-term follow up (maybe a new guidance coming soon). The potential approval of this product next month is an important step for the CRISPR/Cas9 gene editing field of which there are dozens of other therapies in development.

Olivier JUST

Directeur Qualité | Management qualité, Controle Qualité , Développement et Stratégie Réglementaire PharmD PR/PRI Biomedicaments et Médicaments de Thérapie Innovante GMP, GLP, GCTP, ISO et ICH

12mo

Well said

Like
Reply

To view or add a comment, sign in

Explore topics